Antiviral Drugs - Spain

Spain

In Spain, the revenue in the Antiviral Drugs market is estimated to reach €0.55bn by the year 2024.
It is anticipated that the revenue will exhibit a compound annual growth rate (CAGR 2024-2029) of 1.41%, leading to a market volume of €0.59bn by 2029.
When compared globally, United States is projected to generate the highest revenue, amounting to €28,420.00m in 2024.
The demand for antiviral drugs in Spain has increased due to the country's high prevalence of viral infections.

Key regions: Brazil, India, Australia, United States, United Kingdom

Marché

Région

Comparaison de régions

Monnaie

Analyst Opinion

The Antiviral Drugs market in Spain has experienced significant growth in recent years, driven by a variety of factors.

Customer preferences: Customers in Spain are increasingly seeking antiviral drugs that are effective against a wide range of viruses, including both common and emerging strains. In addition, there is a growing demand for antiviral drugs that are easy to administer and have minimal side effects.

Trends in the market: One of the key trends in the Antiviral Drugs market in Spain is the increasing focus on research and development of new antiviral drugs. This is being driven by the need to combat emerging viral diseases such as COVID-19, as well as the desire to improve the effectiveness of existing drugs. Another trend is the growing popularity of combination therapies, which involve the use of multiple antiviral drugs in combination to increase their effectiveness.

Local special circumstances: Spain has a large elderly population, which is particularly vulnerable to viral diseases. As a result, there is a significant demand for antiviral drugs that are effective against common viral infections such as influenza and respiratory syncytial virus (RSV). In addition, Spain has a high incidence of hepatitis C, which has led to a focus on the development of new and more effective antiviral drugs for this condition.

Underlying macroeconomic factors: The growth of the Antiviral Drugs market in Spain is being driven by a variety of macroeconomic factors, including increasing investment in research and development, a growing focus on public health, and the rising incidence of viral diseases. In addition, the Spanish government has implemented policies to encourage the development of new antiviral drugs, such as tax incentives and streamlined regulatory processes. These factors are expected to continue to drive growth in the Antiviral Drugs market in Spain in the coming years.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.